source: The Journal of the American Medical Association
N. Jewel Samadder, Deborah W. Neklason, Kenneth M. Boucher, Kathryn R. Byrne, Priyanka Kanth, Wade Samowitz, David Jones, Sean V. Tavtigian, Michelle W. Done, Therese Berry, Kory Jasperson, Lisa Pappas, Laurel Smith, Danielle Sample, Rian Davis, Matthew K. Topham, Patrick Lynch, Elena Strait, Wendy McKinnon, Randall W. Burt, Scott K. Kuwada
Importance Patients with familial adenomatous polyposis (FAP) are at markedly increased risk for duodenal polyps and cancer. Surgical and endoscopic management of duodenal neoplasia is difficult and chemoprevention has not been successful.
Objective To evaluate the effect of a combination of sulindac and erlotinib on duodenal adenoma regression in patients with FAP.
University of Utah, University of Texas MD Anderson Cancer Center, Penrose Hospital, University of Vermont Cancer Center, University of Hawaii